These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31131319)

  • 1. Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor.
    Iwai K; Nambu T; Dairiki R; Ohori M; Yu J; Burke K; Gotou M; Yamamoto Y; Ebara S; Shibata S; Hibino R; Nishizawa S; Miyazaki T; Homma M; Oguro Y; Imada T; Cho N; Uchiyama N; Kogame A; Takeuchi T; Kurasawa O; Yamanaka K; Niu H; Ohashi A
    Sci Adv; 2019 May; 5(5):eaav3660. PubMed ID: 31131319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
    Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
    Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-
    Kurasawa O; Miyazaki T; Homma M; Oguro Y; Imada T; Uchiyama N; Iwai K; Yamamoto Y; Ohori M; Hara H; Sugimoto H; Iwata K; Skene R; Hoffman I; Ohashi A; Nomura T; Cho N
    J Med Chem; 2020 Feb; 63(3):1084-1104. PubMed ID: 31895562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
    Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
    BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
    Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY
    EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.
    Inoue M; Yoshimura M; Kobayashi M; Morinibu A; Itasaka S; Hiraoka M; Harada H
    Sci Rep; 2015 Oct; 5():15666. PubMed ID: 26503893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
    Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R
    Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
    Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
    Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
    Menichincheri M; Albanese C; Alli C; Ballinari D; Bargiotti A; Caldarelli M; Ciavolella A; Cirla A; Colombo M; Colotta F; Croci V; D'Alessio R; D'Anello M; Ermoli A; Fiorentini F; Forte B; Galvani A; Giordano P; Isacchi A; Martina K; Molinari A; Moll JK; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pillan A; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Vianello P; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2010 Oct; 53(20):7296-315. PubMed ID: 20873740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of AS-0141, a Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers.
    Irie T; Asami T; Sawa A; Uno Y; Taniyama C; Funakoshi Y; Masai H; Sawa M
    J Med Chem; 2021 Oct; 64(19):14153-14164. PubMed ID: 34607435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors.
    Zhou X; Ouerdani A; Diderichsen PM; Gupta N
    J Clin Pharmacol; 2022 Mar; 62(3):422-433. PubMed ID: 34564871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.
    Fu G; Somasundaram RT; Jessa F; Srivastava G; MacMillan C; Witterick I; Walfish PG; Ralhan R
    Oncotarget; 2016 Mar; 7(13):17162-81. PubMed ID: 26934445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.
    Lieu CH; Klauck PJ; Henthorn PK; Tentler JJ; Tan AC; Spreafico A; Selby HM; Britt BC; Bagby SM; Arcaroli JJ; Messersmith WA; Pitts TM; Eckhardt SG
    Oncotarget; 2015 Oct; 6(33):34561-72. PubMed ID: 26439693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.
    Micel LN; Tentler JJ; Tan AC; Selby HM; Brunkow KL; Robertson KM; Davis SL; Klauck PJ; Pitts TM; Gangolli E; Fabrey R; O'Connell SM; Vincent PW; Eckhardt SG
    Mol Cancer Ther; 2015 Feb; 14(2):317-25. PubMed ID: 25376610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
    Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
    Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
    Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
    Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade.
    Morita TY; Yu J; Kashima Y; Kamata R; Yamamoto G; Minamide T; Mashima C; Yoshiya M; Sakae Y; Yamauchi T; Hakozaki Y; Kageyama SI; Nakamura A; Lightcap E; Tanaka K; Niu H; Kannan K; Ohashi A
    Nat Commun; 2023 Nov; 14(1):7490. PubMed ID: 37980406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.